176 related articles for article (PubMed ID: 26083364)
21. Results from implementing updated 2012 World Health Organization Guidance on early-warning indicators of HIV drug resistance in Zimbabwe.
Mungati M; Mhangara M; Dzangare J; Mugurungi O; Apollo T; Gonese E; Kilmarx PH; Chakanyuka-Musanhu CC; Shambira G; Tshimanga M
J Epidemiol Res; 2016; 2(2):85-91. PubMed ID: 29862318
[TBL] [Abstract][Full Text] [Related]
22. Progress of implementation of the World Health Organization strategy for HIV drug resistance control in Latin America and the Caribbean.
Ravasi G; Jack N; Alonso Gonzalez M; Sued O; Pérez-Rosales MD; Gomez B; Vila M; Riego Ad; Ghidinelli M
Rev Panam Salud Publica; 2011 Dec; 30(6):657-62. PubMed ID: 22358418
[TBL] [Abstract][Full Text] [Related]
23. Monitoring HIV Drug Resistance: Early Warning Indicators to Assess Performance of Thailand's Antiretroviral Treatment Program.
Lertpiriyasuwat C; Teeraratkul A; Suchonwanich Y; Chatharojwong N; Phokasawad K; Yuktanon P; Pattarapayoon N; Bhakeecheep S; Bertagnolio S; Roels TH; Thanprasertsuk S
J Med Assoc Thai; 2017 Sep; 100(9):944-952. PubMed ID: 29861515
[TBL] [Abstract][Full Text] [Related]
24. Early warning indicators of HIV drug resistance in the southern highlands region of Tanzania: Lessons from a cross-sectional surveillance study.
Khamadi SA; Mavere C; Bahemana E; Lwilla A; Mizinduko M; Bwigane S; Peter A; Makando J; Peter B; Agaba P; Shah N; Julu B; Ganesan K; Coakley P; Lee EH
PLOS Glob Public Health; 2023; 3(3):e0000929. PubMed ID: 36996096
[TBL] [Abstract][Full Text] [Related]
25. Population-based monitoring of HIV drug resistance in Namibia with early warning indicators.
Hong SY; Jonas A; Dumeni E; Badi A; Pereko D; Blom A; Muthiani VS; Shiningavamwe AN; Mukamba J; Andemichael G; Barbara R; Bennett DE; Jordan MR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):27-31. PubMed ID: 20838224
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
[TBL] [Abstract][Full Text] [Related]
28. HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high.
Kasang C; Kalluvya S; Majinge C; Stich A; Bodem J; Kongola G; Jacobs GB; Mlewa M; Mildner M; Hensel I; Horn A; Preiser W; van Zyl G; Klinker H; Koutsilieri E; Rethwilm A; Scheller C; Weissbrich B
PLoS One; 2011; 6(8):e23091. PubMed ID: 21886779
[TBL] [Abstract][Full Text] [Related]
29. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries.
Bennett DE; Jordan MR; Bertagnolio S; Hong SY; Ravasi G; McMahon JH; Saadani A; Kelley KF
Clin Infect Dis; 2012 May; 54 Suppl 4(Suppl 4):S280-9. PubMed ID: 22544188
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of early warning indicators for HIV drug resistance in antiretroviral therapy clinics in Zimbabwe.
Dzangare J; Gonese E; Mugurungi O; Shamu T; Apollo T; Bennett DE; Kelley KF; Jordan MR; Chakanyuka C; Cham F; Banda RM
Clin Infect Dis; 2012 May; 54 Suppl 4(Suppl 4):S313-6. PubMed ID: 22544194
[TBL] [Abstract][Full Text] [Related]
31. Individual and healthcare supply-related HIV transmission factors in HIV-positive patients enrolled in the antiretroviral treatment access program in the Centre and Littoral regions in Cameroon (ANRS-12288 EVOLCam survey).
Coulaud PJ; Sow A; Sagaon-Teyssier L; Ndiaye K; Maradan G; Laurent C; Spire B; Vidal L; Kuaban C; Boyer S;
PLoS One; 2022; 17(4):e0266451. PubMed ID: 35385535
[TBL] [Abstract][Full Text] [Related]
32. Implementing early-warning indicators of HIV drug resistance in the Caribbean.
Jack N; Ravasi G; Schrooten W; Sutherland D; Ghidinelli M; Del Riego A
Clin Infect Dis; 2012 May; 54 Suppl 4():S290-3. PubMed ID: 22544189
[TBL] [Abstract][Full Text] [Related]
33. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
Bennett DE; Bertagnolio S; Sutherland D; Gilks CF
Antivir Ther; 2008; 13 Suppl 2():1-13. PubMed ID: 18578063
[TBL] [Abstract][Full Text] [Related]
34. The prevalence of pre-treatment and acquired HIV drug resistance in Vietnam: a nationally representative survey, 2017-2018.
Dat VQ; Anh NTL; Van Nghia K; Linh NT; Thu HHK; Tam TTM; Ton T; Anh LQ; Phuc ND; Huong PTT; Nhan DT; Hai NH; Bertagnolio S; Crisp AM; Inzaule S; Dean NE; Jordan MR; Nguyen VTT
J Int AIDS Soc; 2022 Feb; 25(2):e25857. PubMed ID: 35194954
[TBL] [Abstract][Full Text] [Related]
35. Monitoring prevention or emergence of HIV drug resistance: results of a population-based foundational survey of early warning indicators in mainland Tanzania.
Juma JM; Tiberio JK; Abuya MI; Kilama BK; Somi GR; Sambu V; Banda R; Jullu BS; Ramadhani AA
BMC Infect Dis; 2014 Apr; 14():196. PubMed ID: 24725750
[TBL] [Abstract][Full Text] [Related]
36. The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.
Hong SY; Nachega JB; Kelley K; Bertagnolio S; Marconi VC; Jordan MR
Infect Disord Drug Targets; 2011 Apr; 11(2):124-33. PubMed ID: 21406052
[TBL] [Abstract][Full Text] [Related]
37. Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients.
Kiertiburanakul S; Chaiwarith R; Sirivichayakul S; Ditangco R; Jiamsakul A; Li PC; Kantipong P; Lee C; Ratanasuwan W; Kamarulzaman A; Sohn AH; Sungkanuparph S;
PLoS One; 2013; 8(6):e62057. PubMed ID: 23826076
[TBL] [Abstract][Full Text] [Related]
38. Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines.
Fokam J; Takou D; Santoro MM; Akonie HZ; Kouanfack C; Ceccherini-Silberstein F; Colizzi V; Perno CF; Ndjolo A
AIDS Res Hum Retroviruses; 2016 Apr; 32(4):329-33. PubMed ID: 26602836
[TBL] [Abstract][Full Text] [Related]
39. Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria.
Ugbena R; Aberle-Grasse J; Diallo K; Bassey O; Jelpe T; Rottinghaus E; Azeez A; Akpan R; Muhammad M; Shanmugam V; Singh S; Yang C
Clin Infect Dis; 2012 May; 54 Suppl 4():S375-80. PubMed ID: 22544206
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).
Liégeois F; Eymard-Duvernay S; Boyer S; Maradan G; Kouanfack C; Domyeum J; Boyer V; Mpoudi-Ngolé E; Spire B; Delaporte E; Vidal L; Kuaban C; Laurent C;
HIV Med; 2019 Jan; 20(1):38-46. PubMed ID: 30362279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
